CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.

IF 12 1区 医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Molecular Therapy Pub Date : 2025-04-02 Epub Date: 2025-02-28 DOI:10.1016/j.ymthe.2025.02.035
Tassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, Dennis F G Remst, Marijke F Toes, Anne K Wouters, Renate S Hagedoorn, J H Frederik Falkenburg, Mirjam H M Heemskerk
{"title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.","authors":"Tassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, Dennis F G Remst, Marijke F Toes, Anne K Wouters, Renate S Hagedoorn, J H Frederik Falkenburg, Mirjam H M Heemskerk","doi":"10.1016/j.ymthe.2025.02.035","DOIUrl":null,"url":null,"abstract":"<p><p>Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B∗07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM. In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.</p>","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":" ","pages":"1642-1658"},"PeriodicalIF":12.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11997489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2025.02.035","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B∗07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM. In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CAR 介导的目标识别限制了 TCR 和 CAR 双受体编辑 T 细胞介导的目标识别。
抗原逃逸会影响嵌合抗原受体(CAR-)或T细胞受体(TCR-)工程T细胞的疗效。靶向多种抗原可有效限制抗原逃逸,而将 CAR- 与 TCR- 介导的靶向结合可显著拓宽可靶向抗原的范围。在这里,我们探讨了是否可以利用TCR和CAR联合工程在T细胞上设置双重抗原特异性,以防止多发性骨髓瘤(MM)的抗原逃逸。我们报告了转导表达转基因 TCR 的 CD8 T 细胞的生成情况,TCR 的靶标是 HLA-B*07:02 背景下转录辅激活子 BOB1 衍生的多肽,同时还转导表达靶向 BCMA 的 CAR。这些T细胞被称为TRaCR T细胞,它们能有效识别对BOB1 TCR或BCMA CAR T细胞都有抗性的靶细胞,这说明它们具有普遍的双重特异性。然而,在两种抗原都存在的情况下,靶细胞识别优先通过 CAR 实现,从而影响了 TCR 介导的靶细胞识别。重要的是,在体内异源 MM 模型中,缺乏 BCMA 表达的肿瘤细胞因此获得了生存优势。总之,我们证明了TRaCR T细胞的一般双重特异性,但建议在使用TRaCR T细胞作为靶向异质性肿瘤的策略时要谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy
Molecular Therapy 医学-生物工程与应用微生物
CiteScore
19.20
自引率
3.20%
发文量
357
审稿时长
3 months
期刊介绍: Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.
期刊最新文献
Innovative approach in malaria research: Harnessing CRISPR-Cas9 for antimalarial drug-resistance studies in Africa. Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies. Igniting CAR-NKT cells with IL-18. PKC activators improve the function of biogenesis-deficient CFTR channels. A reproducible and physiologically relevant human iPSC-derived platform for in vitro modeling of the neurocardiac junction
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1